Natus Medical Inc NTUS
Institutional shares held
167,118
0
calls
0
puts
Total value of holdings
$0
$0
calls
$0
puts
Market Cap
$1.14B
34,582,900
Shares Out.
Institutional ownership
0.48%
# of Institutions
3
We take great care to ensure that the data presented and summarized in this overview for NATUS MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NTUS
Top Purchases
Top Sells
About NTUS
Insider Transactions at NTUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2022
|
Alice D. Schroeder Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,406
-100.0%
|
$739,398
$33.5 P/Share
|
|
Jul 21
2022
|
Thomas Joseph Sullivan President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
720,903
-100.0%
|
$23,789,799
$33.5 P/Share
|
|
Jul 21
2022
|
Thomas Joseph Sullivan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
648,554
+47.36%
|
-
|
|
Jul 21
2022
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,509
-100.0%
|
$6,616,797
$33.5 P/Share
|
|
Jul 21
2022
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
61,966
+23.61%
|
-
|
|
Jul 21
2022
|
Bryant M Moore Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,114
-100.0%
|
$333,762
$33.5 P/Share
|
|
Jul 21
2022
|
Joshua Levine Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,387
-100.0%
|
$1,233,771
$33.5 P/Share
|
|
Jul 21
2022
|
Lisa Wipperman Heine Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,287
-100.0%
|
$867,471
$33.5 P/Share
|
|
Jul 21
2022
|
Eric Guerin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,114
-100.0%
|
$333,762
$33.5 P/Share
|
|
Jul 21
2022
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
181,846
-100.0%
|
$6,000,918
$33.5 P/Share
|
|
Jul 21
2022
|
Benjamin Drew Davies Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
106,034
+36.83%
|
-
|
|
Jul 21
2022
|
Ilan Daskal Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,937
-100.0%
|
$624,921
$33.5 P/Share
|
|
Jul 21
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,374
-100.0%
|
$2,751,342
$33.5 P/Share
|
|
Jul 21
2022
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,056
+29.6%
|
-
|
|
Jun 15
2022
|
Ilan Daskal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+21.14%
|
-
|
|
Jun 15
2022
|
Eric Guerin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+29.91%
|
-
|
|
Jun 15
2022
|
Lisa Wipperman Heine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+16.18%
|
-
|
|
Jun 15
2022
|
Joshua Levine Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+11.95%
|
-
|
|
Jun 15
2022
|
Bryant M Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,315
+29.91%
|
-
|
|
Jun 15
2022
|
Alice D. Schroeder Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+18.47%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders